Limula SA is a start-up company based in Lausanne, Switzerland. Our multidisciplinary team provides a platform technology to enable scale out of cell therapy manufacturing directly at the point of care, through automation on our patented bioreactor.

Cell & gene therapies (CGT), such as CAR T-cells, are the most advanced personalised medicines, but their production remains extremely challenging and expensive, limiting patient access. By combining our expertise and unique innovative tool, we support biotech companies with CGT assets or CDMO with CGT customers in their process development, at all stages of the product life cycle, from pre-clinical R&D to patient batch production. Limula SA provides a platform technology to enable scale out of cell therapy manufacturing. Our innovative solution is composed of a mechatronic device for process automation, and a single-use plastic kit containing the core bioreactor technology. The patented design features of our technology enable unique functionalities, including in-situ centrifugation, allowing keeping the precious cells sample in the same container along the entire manufacturing process.